Revenue: As of FY2025 Q1, the actual value is USD 11.43 M.EPS: As of FY2025 Q1, the actual value is USD -0.84.EBIT: As of FY2025 Q1, the actual value is USD -10.49 M.<h3>Segment Revenue</h3><ul><li>Cell Therapy: $264,000 for the three months ended March 31, 2025.</li><li>BioBanking: $1,408,000 for the three months ended March 31, 2025.</li><li>Degenerative Disease: $9,754,000 for the three months ended March 31, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: Net loss of $19,754,000 for the three months ended March 31, 2025, compared to a net loss of $22,013,000 for the same period in 2024.</li><li>Operating Profit: Loss from operations of $10,486,000 for the three months ended March 31, 2025, compared to a loss of $7,376,000 for the same period in 2024.</li><li>Operating Costs: Total operating expenses of $21,912,000 for the three months ended March 31, 2025, compared to $22,057,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $2,993,000 for the three months ended March 31, 2025, compared to $4,403,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of Warrant Liabilities: $242,000 for the three months ended March 31, 2025, compared to - $8,875,000 for the same period in 2024.</li><li>Change in Fair Value of Debt: - $12,000 for the three months ended March 31, 2025, compared to $81,000 for the same period in 2024.</li><li>Loss on Debt Extinguishment: - $5,736,000 for the three months ended March 31, 2025, compared to - $3,908,000 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to submit a 510(k) application for Celularity Tendon Wrap (CTW) in the second half of 2025 and advance the development of FUSE Bone Void Filler (FUSE) with the objective of a 510(k) filing in the second half of 2026.</li><li>Non-Core Business: The company is exploring opportunities to diversify its biobanking business, including adult cell banking.</li><li>Priority: The company is actively seeking to secure additional outside capital to fund its operations and investments.</li></ul>

Celularity - CW26 | 10-Q: FY2025 Q1 Revenue: USD 11.43 M